Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680686 | 0.91 | HTT (0.34) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL1914630 | 0.82 | ATM (0.31) | HTT | |
| SCHEMBL5256302 | 0.82 | ATM (0.31) | HTT | |
| SCHEMBL528916 | 0.82 | ATM (0.31) | HTT | |
| SCHEMBL24091149 | 0.79 | GNAI3 (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL22752365 | 0.79 | GNAI3 (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL21291267 | 0.78 | OPRM1 (0.30) | OPRM1 | |
| SCHEMBL22778663 | 0.77 | GNAI3 (0.36) | GNAI3GNAO1GNAI1 | |
| SCHEMBL672564 | 0.76 | HRH4 (0.34) | HTT | |
| SCHEMBL530173 | 0.76 | HRH4 (0.34) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3844159-A1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171521-A1 | ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110014271-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2011-01-20 | — | — | US | disclosed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029188-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | GRIN2D 2989/4885GRIN3B 2086/4885CHRM2 3932/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | GRIN2D 3680/4885GRIN3B 2801/4885CHRM2 4855/4885 |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | GRIN2D 4147/4885GRIN3B 3412/4885CHRM2 4731/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | GRIN2D 4746/4885GRIN3B 4594/4885CHRM2 4841/4885 |
| US-20210171521-A1 | ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION | ADRB3, FPR3, RTN3 | GRIN2D 707/4885GRIN3B 58/4885CHRM2 641/4885 |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PTP4A1, PPP5C | GRIN2D 4704/4885GRIN3B 4587/4885CHRM2 4837/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | GRIN2D 4106/4885GRIN3B 3243/4885CHRM2 4673/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | GRIN2D 569/4885GRIN3B 31/4885CHRM2 2158/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | GRIN2D 4147/4885GRIN3B 3412/4885CHRM2 4731/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | GRIN2D 4746/4885GRIN3B 4594/4885CHRM2 4841/4885 |
| US-11548893-B2 | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection | ADRB3, FPR3, RTN3 | GRIN2D 707/4885GRIN3B 58/4885CHRM2 641/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | GRIN2D 4106/4885GRIN3B 3243/4885CHRM2 4673/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | GRIN2D 4425/4885GRIN3B 3796/4885CHRM2 4784/4885 |
| US-20110014271-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | GRIN2D 2989/4885GRIN3B 2086/4885CHRM2 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.